On January 18, 2019, John Steuart resigned as a member of the Board of Directors of Natera, Inc., effective January 24, 2019. Mr. Steuart’s resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. On January 24, 2019, the Board appointed Gail Marcus as Chair of the Audit Committee. Ms. Marcus joined the Board in March 2017 and currently serves as the Chair of the Nominating and Corporate Governance Committee.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
NATERA, INC. 
